Author name: Layne

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute (“Moffitt”) showing preclinical data from the company’s unique delivery approach that unlocks the powerful effects of …

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting Read More »

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, …

Dyve Announces Poster Presentation at 2023 AACR Annual Meeting Read More »

CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that Tatyana Beldock has joined Dyve’s Board of Directors. Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are thrilled to have Tatyana join our Board. Tatyana brings a wealth of business, investment, and strategic experience to our …

Dyve Biosciences Appoints Tatyana Beldock to Board of Directors Read More »

When: November 14, 2022Where: Philadelphia, PATopic: “The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study”.  Presented by Dr. Puja Khanna, the study provides evidence of systemic pH modulation demonstrated as part of our TARGETS …

Dyve’s TARGETS Phase 2 Study Abstract Presented at ACR Read More »

When: October 24 and 25, 2022  Where: Boston, MATopic: “Targeting TME Acidity and Turbocharging Immunotherapy with Novel Drug Delivery” We are excited to share how Dyve’s patented emulsion chemistry delivers a broad range of molecules never before possible, turning the skin tissue into a tunable drug delivery portal for locally optimized or systemic delivery.